← back to search

Lluı́s Castells

Universitat Autònoma de Barcelona · ES
Area of research
Hepatology · Epidemiology
Research interest
Research interests include Liver Disease and Transplantation, Hepatitis C virus research, Organ Transplantation Techniques and Outcomes, and Liver Disease Diagnosis and Treatment.
h-index
40
citations
9,080
works
250
NIH funding
primary concept
Medicine
email

Recent publications

Assessment of sarcopenia in cirrhosis: A practical approach using thigh and psoas ultrasound, bioimpedance, and anthropometry.
2026cited by 0position: contributordoi
Exhausted/senescent CD4+ T cells as predictors of vaccine failure and severe coronavirus disease 2019 in solid organ transplant recipients
American Journal of Transplantation 2026cited by 0position: contributordoi
Frailty and sarcopenia in patients with acute-on-chronic liver failure: Assessment and risk in the liver transplant setting.
2024cited by 4position: contributordoi
High intrapatient variability of tacrolimus exposure associated with poorer outcomes in liver transplantation.
2022cited by 17position: contributordoi
Non-Invasive Tests of Liver Fibrosis Help in Predicting the Development of Hepatocellular Carcinoma among Patients with NAFLD.
2022cited by 10position: contributordoi
Sinusoidal obstruction syndrome after liver transplantation: A multicenter observational study.
2022cited by 4position: contributordoi
COVID-19 in liver transplant candidates: pretransplant and post-transplant outcomes - an ELITA/ELTR multicentre cohort study
Gut 2021cited by 39position: middledoi
Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients
American Journal of Transplantation 2021cited by 32position: contributordoi
Low seroprevalence of SARS-CoV-2 antibodies in a liver transplant cohort.
2021cited by 4position: contributordoi
Long-term effects of COVID-19 in solid organ transplantation recipients.
2021cited by 2position: contributordoi
Protective Role of Tacrolimus, Deleterious Role of Age and Comorbidities in Liver Transplant Recipients With Covid-19: Results From the ELITA/ELTR Multi-center European Study
Gastroenterology 2020cited by 158position: middledoi
Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection
Liver Transplantation 2016cited by 78position: middledoi
Treatment of severe recurrent hepatitis C after liver transplantation in <scp>HIV</scp> infected patients using sofosbuvir‐based therapy
Alimentary Pharmacology & Therapeutics 2016cited by 13position: middledoi
Benefit of Treating Hepatocellular Carcinoma Recurrence after Liver Transplantation and Analysis of Prognostic Factors for Survival in a Large Euro-American Series
Annals of Surgical Oncology 2014cited by 178position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 7 papers (2021–2026)Isabel Campos-Varela · Hebron University5 papers (2021–2026)Vı́ctor Vargas · University of Chile3 papers (2022–2026)Cristina Dopazo · Instituto de Salud Carlos III3 papers (2021–2026) · 3 papers (2022–2026)Sergi Quiroga · 2 papers (2024–2026)Ibai Los-Arcos · Hebron University2 papers (2021–2021)Macarena Simon Talero · Hebron University2 papers (2024–2026)Francesc Moreso · Unidad de Investigación en cuidados y servicios de salud (Investén-isciii)2 papers (2021–2022) · 1 papers (2014–2014)Carmelo Loinaz · Hospital Universitario Fundación Alcorcón1 papers (2022–2022) · 1 papers (2014–2014) · 1 papers (2016–2016)Isabel Campos‐Varela · Universidade de Santiago de Compostela1 papers (2016–2016)Nicolás Goldaracena · Johannes Gutenberg University Mainz1 papers (2014–2014)Jennifer L. Dodge · University of Southern California1 papers (2026–2026) · 1 papers (2014–2014)Juan M. Pericàs · NIHR Birmingham Biomedical Research Centre1 papers (2022–2022)Jerome Laurence · The University of Sydney1 papers (2014–2014) · 1 papers (2016–2016)